Tenaya Therapeutics Reports $1.1M Collaboration Revenue and $43.4M Net Loss in Q2 2026

Tenaya Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a collaboration revenue of $1.1 million, a significant increase from zero in the same period last year. This revenue was primarily derived from an upfront fee and reimbursements for research and development activities under a collaboration agreement with Alnylam Pharmaceuticals. However, the company incurred a net loss of $43.4 million for the quarter, compared to a loss of $23.3 million in the prior year, reflecting an 86% increase in losses attributed to higher operating expenses, including a $21.8 million impairment loss related to leasehold improvements and manufacturing equipment.

Total operating expenses for the quarter reached $45.2 million, an 88% increase from $24.1 million in the same quarter of 2025. The rise in expenses was driven by the impairment loss and a net loss on lease termination of $1.4 million, alongside a decrease in research and development costs, which fell by 4% to $16.6 million. General and administrative expenses also decreased by 19% to $5.4 million, primarily due to lower stock-based compensation and professional fees.

For the first half of 2026, Tenaya reported a total revenue of $1.3 million, with a net loss of $62.7 million, up from a loss of $50.1 million in the same period last year. The company’s cash and cash equivalents stood at $78.1 million as of June 30, 2026, down from $100.5 million at the end of 2025. The decrease in cash was attributed to ongoing operational losses, although management believes the current cash reserves will be sufficient to fund operations for at least the next twelve months.

Strategically, Tenaya has focused on advancing its clinical-stage gene therapy candidates, TN-201 and TN-401, both of which are currently in Phase 1b/2 trials. The company has also entered into a collaboration agreement with Alnylam to explore novel gene targets for cardiovascular disease, which is expected to enhance its research capabilities and provide additional funding through reimbursements. The company plans to present further data from its clinical trials in the fourth quarter of 2026 and is engaging with regulatory authorities regarding pivotal trial plans.

Looking ahead, Tenaya anticipates continued operational losses as it advances its product candidates and expands its clinical trials. The company is actively seeking additional funding through equity offerings, collaborations, and other financing options to support its development efforts. The successful commercialization of its therapies remains contingent on achieving regulatory approvals and demonstrating clinical efficacy in ongoing trials.